NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4 and year end 2025 corporate update call on April 2...
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology...
NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces some preliminary (unaudited) financials for Q4-2025 and for...
NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has made major strides in cleaning up its balance sheet with two major...
NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with...
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its...
NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today. The following are the highlights of the Company’s...
NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2025 corporate update call on November 17 th , 2025...
NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , has terminated its ATM (At-The-Market) instrument with investment bank...
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today. The following are the highlights of the...